Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Latin America Oncology Drugs Market by Therapy Modalities (Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy, Others) and by Type (Blood Cancer, Breast Cancer, Gastrointestinal Cancer, Respiratory/Lung Cancer, Skin Cancer, Other Cancers): Global Opportunity Analysis and Industry Forecast, 2023-2032

A02529

Pages: NA

Charts: NA

Tables: NA

Oncology drugs include chemotherapy, hormone therapy, immunotherapy, and other drugs that are useful in the treatment of cancer. According to the CDC, 21.1 million adults were diagnosed with cancer in 2015, which drives the number of oncologic drugs in the market. Whereas in Latin America and the Caribbean about 1.1 million new cancer cases and 600,000 cancer deaths are estimated to occur annually.

Increase in prevalence in cancer, growth in population and more dispatchable money with the older section of the society, and rise in awareness about the treatments, technologies, and the disease itself drive the market growth. However, the high cost involved in new drug development coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies restrain the growth of the market. Nevertheless, advancements in cancer drug research owing to biological/targeted therapies and personalized medicines make way for promising opportunities for pharmaceutical, bio-pharmaceutical, and biotechnology companies engaged in developing cancer drugs.

The Latin America oncology drugs market is segmented on the basis of therapy modality, types of cancer, and country. Based on therapy modalities, the market is divided into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy, and others. By type of cancer, the market is classified into blood cancer, breast cancer, gastrointestinal cancer, respiratory/lung cancer, skin cancer and other cancers. Based on country, the market is studied across Brazil, Argentina, Columbia, Chile, and Peru.

The companies operating in the market are Novartis A.G, F. Hoffmann-La Roche Ltd, Medley Genomics, Eurofarma Laboratrios S.A., Ach Laboratrios Farmacuticos S.A., Laboratorios IMA, Laboratrio Cristlia, Icon Plc., Sanofi S.A, and Laboratoires Pierre Fabre.

Key Benefits

  • The study provides an in-depth analysis of the Latin America oncology drug market along with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates the various forms of available oncology drugs.
  • Key players are profiled and their strategies are analyzed thoroughly to predict the competitive outlook of the market.
  • By geography, the market is analyzed across Latin America such as Brazil, Argentina, Columbia, Peru, and Chile.

 Key Market Segments

  • By Therapy Modalities
    • Chemotherapy
    • Targeted Therapy
    • Immunotherapy (Biologic Therapy)
    • Hormonal Therapy
    • Others
  • By Type
    • Blood Cancer
    • Breast Cancer
    • Gastrointestinal Cancer
    • Respiratory/Lung Cancer
    • Skin Cancer
    • Other Cancers
  • By Region
    • Latin America
      • Brazil
      • Argentina
      • Columbia
      • Chile
      • Peru
      • Other Latin America Countries

 
Key Market Players

  • Medley Genomics
  • F. Hoffmann-La Roche Ltd.
  • Novartis A.G
  • Sanofi S.A
  • Laboratoires Pierre Fabre
  • Icon Plc.
  • Eurofarma Laboratrios S.A.
  • Ach Laboratrios Farmacuticos S.A.
  • Laboratorios IMA
  • Laboratrio Cristlia

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: LATIN AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY MODALITIES

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Therapy Modalities

    • 4.2. Chemotherapy

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Targeted Therapy

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Immunotherapy (Biologic Therapy)

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Hormonal Therapy

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: LATIN AMERICA ONCOLOGY DRUGS MARKET, BY TYPE

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Type

    • 5.2. Blood Cancer

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Breast Cancer

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Gastrointestinal Cancer

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

    • 5.5. Respiratory/Lung Cancer

      • 5.5.1. Key Market Trends, Growth Factors and Opportunities

      • 5.5.2. Market Size and Forecast, By Region

      • 5.5.3. Market Share Analysis, By Country

    • 5.6. Skin Cancer

      • 5.6.1. Key Market Trends, Growth Factors and Opportunities

      • 5.6.2. Market Size and Forecast, By Region

      • 5.6.3. Market Share Analysis, By Country

    • 5.7. Other Cancers

      • 5.7.1. Key Market Trends, Growth Factors and Opportunities

      • 5.7.2. Market Size and Forecast, By Region

      • 5.7.3. Market Share Analysis, By Country

  • CHAPTER 6: LATIN AMERICA ONCOLOGY DRUGS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Therapy Modalities

      • 6.2.3. Market Size and Forecast, By Type

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S.

        • 6.2.5.1 Market size and forecast, therapy modalities

        • 6.2.5.2 Market size and forecast, type

      • 6.2.6. Canada

        • 6.2.6.1 Market size and forecast, therapy modalities

        • 6.2.6.2 Market size and forecast, type

      • 6.2.7. Mexico

        • 6.2.7.1 Market size and forecast, therapy modalities

        • 6.2.7.2 Market size and forecast, type

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Therapy Modalities

      • 6.3.3. Market Size and Forecast, By Type

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France

        • 6.3.5.1 Market size and forecast, therapy modalities

        • 6.3.5.2 Market size and forecast, type

      • 6.3.6. Germany

        • 6.3.6.1 Market size and forecast, therapy modalities

        • 6.3.6.2 Market size and forecast, type

      • 6.3.7. Italy

        • 6.3.7.1 Market size and forecast, therapy modalities

        • 6.3.7.2 Market size and forecast, type

      • 6.3.8. Spain

        • 6.3.8.1 Market size and forecast, therapy modalities

        • 6.3.8.2 Market size and forecast, type

      • 6.3.9. UK

        • 6.3.9.1 Market size and forecast, therapy modalities

        • 6.3.9.2 Market size and forecast, type

      • 6.3.10. Russia

        • 6.3.10.1 Market size and forecast, therapy modalities

        • 6.3.10.2 Market size and forecast, type

      • 6.3.11. Rest Of Europe

        • 6.3.11.1 Market size and forecast, therapy modalities

        • 6.3.11.2 Market size and forecast, type

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Therapy Modalities

      • 6.4.3. Market Size and Forecast, By Type

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China

        • 6.4.5.1 Market size and forecast, therapy modalities

        • 6.4.5.2 Market size and forecast, type

      • 6.4.6. Japan

        • 6.4.6.1 Market size and forecast, therapy modalities

        • 6.4.6.2 Market size and forecast, type

      • 6.4.7. India

        • 6.4.7.1 Market size and forecast, therapy modalities

        • 6.4.7.2 Market size and forecast, type

      • 6.4.8. South Korea

        • 6.4.8.1 Market size and forecast, therapy modalities

        • 6.4.8.2 Market size and forecast, type

      • 6.4.9. Australia

        • 6.4.9.1 Market size and forecast, therapy modalities

        • 6.4.9.2 Market size and forecast, type

      • 6.4.10. Thailand

        • 6.4.10.1 Market size and forecast, therapy modalities

        • 6.4.10.2 Market size and forecast, type

      • 6.4.11. Malaysia

        • 6.4.11.1 Market size and forecast, therapy modalities

        • 6.4.11.2 Market size and forecast, type

      • 6.4.12. Indonesia

        • 6.4.12.1 Market size and forecast, therapy modalities

        • 6.4.12.2 Market size and forecast, type

      • 6.4.13. Rest of Asia Pacific

        • 6.4.13.1 Market size and forecast, therapy modalities

        • 6.4.13.2 Market size and forecast, type

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Therapy Modalities

      • 6.5.3. Market Size and Forecast, By Type

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil

        • 6.5.5.1 Market size and forecast, therapy modalities

        • 6.5.5.2 Market size and forecast, type

      • 6.5.6. South Africa

        • 6.5.6.1 Market size and forecast, therapy modalities

        • 6.5.6.2 Market size and forecast, type

      • 6.5.7. Saudi Arabia

        • 6.5.7.1 Market size and forecast, therapy modalities

        • 6.5.7.2 Market size and forecast, type

      • 6.5.8. UAE

        • 6.5.8.1 Market size and forecast, therapy modalities

        • 6.5.8.2 Market size and forecast, type

      • 6.5.9. Argentina

        • 6.5.9.1 Market size and forecast, therapy modalities

        • 6.5.9.2 Market size and forecast, type

      • 6.5.10. Rest of LAMEA

        • 6.5.10.1 Market size and forecast, therapy modalities

        • 6.5.10.2 Market size and forecast, type

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Novartis A.G

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. F. Hoffmann-La Roche Ltd.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Medley Genomics

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Eurofarma Laboratrios S.A.

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Ach Laboratrios Farmacuticos S.A.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Laboratorios IMA

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Laboratrio Cristlia

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Icon Plc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Sanofi S.A

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Laboratoires Pierre Fabre

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LATIN AMERICA ONCOLOGY DRUGS MARKET, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 2. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR CHEMOTHERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR TARGETED THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY REGION, 2022-2032 ($MILLION)
  • TABLE 5. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR HORMONAL THERAPY, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL LATIN AMERICA ONCOLOGY DRUGS MARKET, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 8. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR BLOOD CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR BREAST CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR GASTROINTESTINAL CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR RESPIRATORY/LUNG CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR SKIN CANCER, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR OTHER CANCERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. LATIN AMERICA ONCOLOGY DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA LATIN AMERICA ONCOLOGY DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 19. U.S. LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 20. CANADA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 21. CANADA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 22. MEXICO LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 23. MEXICO LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 24. EUROPE LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 25. EUROPE LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 26. EUROPE LATIN AMERICA ONCOLOGY DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 27. FRANCE LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 28. FRANCE LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 29. GERMANY LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 30. GERMANY LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 31. ITALY LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 32. ITALY LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 33. SPAIN LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 34. SPAIN LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 35. UK LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 36. UK LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 37. RUSSIA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 38. RUSSIA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 39. REST OF EUROPE LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 40. REST OF EUROPE LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ASIA-PACIFIC LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 42. ASIA-PACIFIC LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 43. ASIA-PACIFIC LATIN AMERICA ONCOLOGY DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 44. CHINA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 45. CHINA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 46. JAPAN LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 47. JAPAN LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 48. INDIA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 49. INDIA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 50. SOUTH KOREA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 51. SOUTH KOREA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 52. AUSTRALIA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 53. AUSTRALIA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 54. THAILAND LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 55. THAILAND LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 56. MALAYSIA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 57. MALAYSIA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 58. INDONESIA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 59. INDONESIA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 60. REST OF ASIA PACIFIC LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 61. REST OF ASIA PACIFIC LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 62. LAMEA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 63. LAMEA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 64. LAMEA LATIN AMERICA ONCOLOGY DRUGS, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 65. BRAZIL LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 66. BRAZIL LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH AFRICA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 68. SOUTH AFRICA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 69. SAUDI ARABIA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 70. SAUDI ARABIA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 71. UAE LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 72. UAE LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 73. ARGENTINA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 74. ARGENTINA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 75. REST OF LAMEA LATIN AMERICA ONCOLOGY DRUGS, BY THERAPY MODALITIES, 2022-2032 ($MILLION)
  • TABLE 76. REST OF LAMEA LATIN AMERICA ONCOLOGY DRUGS, BY TYPE, 2022-2032 ($MILLION)
  • TABLE 77. NOVARTIS A.G: KEY EXECUTIVES
  • TABLE 78. NOVARTIS A.G: COMPANY SNAPSHOT
  • TABLE 79. NOVARTIS A.G: OPERATING SEGMENTS
  • TABLE 80. NOVARTIS A.G: PRODUCT PORTFOLIO
  • TABLE 81. NOVARTIS A.G: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 82. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 83. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 84. F. HOFFMANN-LA ROCHE LTD.: OPERATING SEGMENTS
  • TABLE 85. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 86. F. HOFFMANN-LA ROCHE LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 87. MEDLEY GENOMICS: KEY EXECUTIVES
  • TABLE 88. MEDLEY GENOMICS: COMPANY SNAPSHOT
  • TABLE 89. MEDLEY GENOMICS: OPERATING SEGMENTS
  • TABLE 90. MEDLEY GENOMICS: PRODUCT PORTFOLIO
  • TABLE 91. MEDLEY GENOMICS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 92. EUROFARMA LABORATRIOS S.A.: KEY EXECUTIVES
  • TABLE 93. EUROFARMA LABORATRIOS S.A.: COMPANY SNAPSHOT
  • TABLE 94. EUROFARMA LABORATRIOS S.A.: OPERATING SEGMENTS
  • TABLE 95. EUROFARMA LABORATRIOS S.A.: PRODUCT PORTFOLIO
  • TABLE 96. EUROFARMA LABORATRIOS S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 97. ACH LABORATRIOS FARMACUTICOS S.A.: KEY EXECUTIVES
  • TABLE 98. ACH LABORATRIOS FARMACUTICOS S.A.: COMPANY SNAPSHOT
  • TABLE 99. ACH LABORATRIOS FARMACUTICOS S.A.: OPERATING SEGMENTS
  • TABLE 100. ACH LABORATRIOS FARMACUTICOS S.A.: PRODUCT PORTFOLIO
  • TABLE 101. ACH LABORATRIOS FARMACUTICOS S.A.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 102. LABORATORIOS IMA: KEY EXECUTIVES
  • TABLE 103. LABORATORIOS IMA: COMPANY SNAPSHOT
  • TABLE 104. LABORATORIOS IMA: OPERATING SEGMENTS
  • TABLE 105. LABORATORIOS IMA: PRODUCT PORTFOLIO
  • TABLE 106. LABORATORIOS IMA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 107. LABORATRIO CRISTLIA: KEY EXECUTIVES
  • TABLE 108. LABORATRIO CRISTLIA: COMPANY SNAPSHOT
  • TABLE 109. LABORATRIO CRISTLIA: OPERATING SEGMENTS
  • TABLE 110. LABORATRIO CRISTLIA: PRODUCT PORTFOLIO
  • TABLE 111. LABORATRIO CRISTLIA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 112. ICON PLC.: KEY EXECUTIVES
  • TABLE 113. ICON PLC.: COMPANY SNAPSHOT
  • TABLE 114. ICON PLC.: OPERATING SEGMENTS
  • TABLE 115. ICON PLC.: PRODUCT PORTFOLIO
  • TABLE 116. ICON PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 117. SANOFI S.A: KEY EXECUTIVES
  • TABLE 118. SANOFI S.A: COMPANY SNAPSHOT
  • TABLE 119. SANOFI S.A: OPERATING SEGMENTS
  • TABLE 120. SANOFI S.A: PRODUCT PORTFOLIO
  • TABLE 121. SANOFI S.A: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 122. LABORATOIRES PIERRE FABRE: KEY EXECUTIVES
  • TABLE 123. LABORATOIRES PIERRE FABRE: COMPANY SNAPSHOT
  • TABLE 124. LABORATOIRES PIERRE FABRE: OPERATING SEGMENTS
  • TABLE 125. LABORATOIRES PIERRE FABRE: PRODUCT PORTFOLIO
  • TABLE 126. LABORATOIRES PIERRE FABRE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LATIN AMERICA ONCOLOGY DRUGS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LATIN AMERICA ONCOLOGY DRUGS MARKET
  • FIGURE 3. SEGMENTATION LATIN AMERICA ONCOLOGY DRUGS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LATIN AMERICA ONCOLOGY DRUGS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLATIN AMERICA ONCOLOGY DRUGS MARKET
  • FIGURE 11. LATIN AMERICA ONCOLOGY DRUGS MARKET SEGMENTATION, BY THERAPY MODALITIES
  • FIGURE 12. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR CHEMOTHERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR TARGETED THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR IMMUNOTHERAPY (BIOLOGIC THERAPY), BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 15. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR HORMONAL THERAPY, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. LATIN AMERICA ONCOLOGY DRUGS MARKET SEGMENTATION, BY TYPE
  • FIGURE 18. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 19. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR BREAST CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 20. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR GASTROINTESTINAL CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 21. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR RESPIRATORY/LUNG CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 22. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR SKIN CANCER, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 23. LATIN AMERICA ONCOLOGY DRUGS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 24. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 25. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 26. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 27. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 28. COMPETITIVE DASHBOARD
  • FIGURE 29. COMPETITIVE HEATMAP: LATIN AMERICA ONCOLOGY DRUGS MARKET
  • FIGURE 30. TOP PLAYER POSITIONING,2022
  • FIGURE 31. NOVARTIS A.G: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. NOVARTIS A.G: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. NOVARTIS A.G: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. F. HOFFMANN-LA ROCHE LTD.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. MEDLEY GENOMICS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. MEDLEY GENOMICS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. MEDLEY GENOMICS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. EUROFARMA LABORATRIOS S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. EUROFARMA LABORATRIOS S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. EUROFARMA LABORATRIOS S.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. ACH LABORATRIOS FARMACUTICOS S.A.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. ACH LABORATRIOS FARMACUTICOS S.A.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. ACH LABORATRIOS FARMACUTICOS S.A.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. LABORATORIOS IMA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. LABORATORIOS IMA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. LABORATORIOS IMA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. LABORATRIO CRISTLIA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. LABORATRIO CRISTLIA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. LABORATRIO CRISTLIA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. ICON PLC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. ICON PLC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. ICON PLC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 55. SANOFI S.A: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 56. SANOFI S.A: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 57. SANOFI S.A: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 58. LABORATOIRES PIERRE FABRE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 59. LABORATOIRES PIERRE FABRE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 60. LABORATOIRES PIERRE FABRE: REVENUE SHARE, BY REGION, 2032 (%)

Purchase Full Report of
Latin America Oncology Drugs Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved